Altimmune to Participate in the Citizens Life Sciences Conference

GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:

The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease.  For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
[email protected]

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
[email protected]

Media Contact:
Jason Spark
Inizio Evoke, Biotech
Phone: 619-849-6005
[email protected]

This press release was published by a CLEAR® Verified individual.

You May Also Be Interested In

• EIB submits Form 18-K/A Amendment No.4 - Unaudited Condensed Semi-annual Financial Statements as at and for the six-month period ended June 30, 2026
• Back to School 2026: GradGuard Urges Families to Look Beyond the Tuition Bill
• Ergodyne Continues Support for Rapidly Growing Cold Chain Workforce with Latest Launch